This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Information about Acute Megakaryocytic Leukemias: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Most recent studies have shown that Acute Megakaryocytic Leukemias shares some biological mechanisms with acute-erythroblastic-leukemia, acute-leukemia, acute-lymphocytic-leukemia, anemia, cytogenetic-abnormality, down-syndrome, dysmyelopoietic-syndromes, fibrosis, leukemia, leukemia-myelocytic-acute, malignant-neoplasms, malignant-paraganglionic-neoplasm, myeloid-leukemia, myeloid-leukemia-chronic, myeloproliferative-disease, myeloproliferative-syndrome-transient, neoplasms, primary-myelofibrosis, thrombocythemia-essential, trisomy.
Among the many pathways, these few ones have gauged particular interests from scientists studying Acute Megakaryocytic Leukemias, and have been seen in publications frequently: Cell Adhesion, Cell Cycle, Cell Cycle Arrest, Cell Differentiation, Cell Division, Cell Growth, Cell Proliferation, Coagulation, Dna Replication, Induction Of Apoptosis, Localization, Megakaryocyte Development, Megakaryocyte Differentiation, Pathogenesis, Peroxidase Reaction, Platelet Aggregation, Secretion, Translation, Transport, Tropism
Quite a number of genes have been found to play important roles in Acute Megakaryocytic Leukemias, such as CD34, CSF2, CTLA4, EPO, FANCB, GATA1, HLA-DQA1, IL3, IL6, ITGA2B, ITGB3, JAK2, KITLG, MPO, NOD2, THPO, TNF. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.